Tags

Type your tag names separated by a space and hit enter

Glutamine: A novel approach to chemotherapy-induced toxicity.

Abstract

Treatment of cancer is associated with short- and long-term side-effects. Cancer produces a state of glutamine deficiency, which is further aggravated by toxic effects of chemotherapeutic agents leading to increased tolerance of tumor to chemotherapy as well as reduced tolerance of normal tissues to the side-effects of chemotherapy. This article reviews the possible role of glutamine supplementation in reducing the serious adverse events in patients treated with anticancer drugs. The literature related to the possible role of glutamine in humans with cancer and the supportive evidence from animal studies was reviewed. Searches were made and the literature was retrieved using PUBMED, MEDLINE, COCHRANE LIBRARY, CENAHL and EMBASE, with a greater emphasis on the recent advances and clinical trials. Glutamine supplementation was found to protect against radiation-induced mucositis, anthracycline-induced cardiotoxicity and paclitaxel-related myalgias/arthralgias. Glutamine may prevent neurotoxicity of paclitaxel, cisplatin, oxaplatin bortezomib and lenolidamide, and is beneficial in the reduction of the dose-limiting gastrointestinal toxic effects of irinotecan and 5-FU-induced mucositis and stomatitis. Dietary glutamine reduces the severity of the immunosuppressive effect induced by methotrexate and improves the immune status of rats recovering from chemotherapy. In patients with acute myeloid leukemia requiring parenteral nutrition, glycyl-glutamine supplementation could hasten neutrophil recovery after intensive myelosuppressive chemotherapy. Current data supports the usefulness of glutamine supplementation in reducing complications of chemotherapy; however, paucity of clinical trials weakens the clear interpretation of these findings.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

    , ,

    Source

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    22754203

    Citation

    Gaurav, Kumar, et al. "Glutamine: a Novel Approach to Chemotherapy-induced Toxicity." Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology, vol. 33, no. 1, 2012, pp. 13-20.
    Gaurav K, Goel RK, Shukla M, et al. Glutamine: A novel approach to chemotherapy-induced toxicity. Indian J Med Paediatr Oncol. 2012;33(1):13-20.
    Gaurav, K., Goel, R. K., Shukla, M., & Pandey, M. (2012). Glutamine: A novel approach to chemotherapy-induced toxicity. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology, 33(1), pp. 13-20. doi:10.4103/0971-5851.96962.
    Gaurav K, et al. Glutamine: a Novel Approach to Chemotherapy-induced Toxicity. Indian J Med Paediatr Oncol. 2012;33(1):13-20. PubMed PMID: 22754203.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Glutamine: A novel approach to chemotherapy-induced toxicity. AU - Gaurav,Kumar, AU - Goel,R K, AU - Shukla,Mridula, AU - Pandey,Manoj, PY - 2012/7/4/entrez PY - 2012/7/4/pubmed PY - 2012/7/4/medline KW - Cancer KW - chemotherapy KW - glutamine KW - toxicity SP - 13 EP - 20 JF - Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology JO - Indian J Med Paediatr Oncol VL - 33 IS - 1 N2 - Treatment of cancer is associated with short- and long-term side-effects. Cancer produces a state of glutamine deficiency, which is further aggravated by toxic effects of chemotherapeutic agents leading to increased tolerance of tumor to chemotherapy as well as reduced tolerance of normal tissues to the side-effects of chemotherapy. This article reviews the possible role of glutamine supplementation in reducing the serious adverse events in patients treated with anticancer drugs. The literature related to the possible role of glutamine in humans with cancer and the supportive evidence from animal studies was reviewed. Searches were made and the literature was retrieved using PUBMED, MEDLINE, COCHRANE LIBRARY, CENAHL and EMBASE, with a greater emphasis on the recent advances and clinical trials. Glutamine supplementation was found to protect against radiation-induced mucositis, anthracycline-induced cardiotoxicity and paclitaxel-related myalgias/arthralgias. Glutamine may prevent neurotoxicity of paclitaxel, cisplatin, oxaplatin bortezomib and lenolidamide, and is beneficial in the reduction of the dose-limiting gastrointestinal toxic effects of irinotecan and 5-FU-induced mucositis and stomatitis. Dietary glutamine reduces the severity of the immunosuppressive effect induced by methotrexate and improves the immune status of rats recovering from chemotherapy. In patients with acute myeloid leukemia requiring parenteral nutrition, glycyl-glutamine supplementation could hasten neutrophil recovery after intensive myelosuppressive chemotherapy. Current data supports the usefulness of glutamine supplementation in reducing complications of chemotherapy; however, paucity of clinical trials weakens the clear interpretation of these findings. SN - 0975-2129 UR - https://www.unboundmedicine.com/medline/citation/22754203/full_citation L2 - http://www.ijmpo.org/article.asp?issn=0971-5851;year=2012;volume=33;issue=1;spage=13;epage=20;aulast=Gaurav DB - PRIME DP - Unbound Medicine ER -